Detailed Information on Publication Record
2011
Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin
STAESSEN, Jan, Lutgarde THIJS, Katarzyna STOLARZ-SKRZYPEK, A. BACCHIERI, John BARTON et. al.Basic information
Original name
Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin
Authors
STAESSEN, Jan (56 Belgium, guarantor), Lutgarde THIJS (56 Belgium), Katarzyna STOLARZ-SKRZYPEK (616 Poland), A. BACCHIERI (380 Italy), John BARTON (372 Ireland), Ezio ESPOSITI (380 Italy), Peter LEEUW (528 Netherlands), Mirosław DŁUŻNIEWSKI (616 Poland), Nicola GLORIOSO (380 Italy), Andrzej JANUSZEWICZ (616 Poland), Paolo MANUNTA (380 Italy), Viktor MILYAGIN (643 Russian Federation), Yuri NIKITIN (643 Russian Federation), Miroslav SOUČEK (203 Czech Republic, belonging to the institution), Chiara LANZANI (380 Italy), Lorena CITTERIO (380 Italy), Mario TIMIO (380 Italy), Andrzej TYKARSKI (616 Poland), P. FERRARI (380 Italy), G. VALENTINI (380 Italy), K. KAWECKA-JASZCZ (616 Poland) and G. BIANCHI (380 Italy)
Edition
Trials, University of Oxford, 2011, 1745-6215
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.496
RIV identification code
RIV/00216224:14110/11:00055577
Organization unit
Faculty of Medicine
UT WoS
000286896900001
Keywords in English
Hypertension; sodium; cardiovascular disease
Tags
International impact
Změněno: 20/4/2012 12:29, Mgr. Michal Petr
Abstract
V originále
The Ouabain and Adducin for Specific Intervention on Sodium in Hypertension (OASIS-HT) Trial was a phase-2 dose-finding study of rostafuroxin, a digitoxygenin derivative, which selectively antagonizes the effects of endogenous ouabain (EO) on Na+,K+-ATPase and mutated adducin. Rostafuroxin lowered blood pressure (BP) in some animal models and in humans.